Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
December 19, 2024 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies™, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S....
Arbor Biotechnologies to Highlight New Preclinical Data Supporting Advancement of Pipeline Programs and Knock-In Applicability of Type V Nucleases at Upcoming Medical and Scientific Meetings
October 22, 2024 16:17 ET
|
Arbor Biotechnologies Inc
Oral presentation at ASN on lead program, ABO-101 for primary hyperoxaluria type 1 (PH1), supporting in vivo proof of pharmacology. On-track for year-end IND/CTA filing.Oral presentation at ALS One...
Arbor Biotechnologies Presents Data Supporting Clinical Development of ABO-101 and Robust Potential of Platform to Enable Therapeutic Programs at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
May 09, 2024 06:00 ET
|
Arbor Biotechnologies Inc
Presented data which, along with ongoing IND-enabling studies, demonstrate efficacy and pharmacology of ABO-101 in non-human primates (NHPs), supporting continued development as a potential novel gene...
Arbor Biotechnologies Announces Acquisition of Serendipity
May 08, 2024 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies to Present Data Supporting Therapeutic Programs in PH1 and ALS, and the Discovery of a Novel Type V Nuclease at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
April 22, 2024 17:09 ET
|
Arbor Biotechnologies Inc
- Oral and poster presentations showcase data demonstrating pipeline progress and continued advancement of Arbor’s pipeline programs toward the clinic - Oral presentation with data validating...
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
January 03, 2024 08:01 ET
|
Arbor Biotechnologies Inc
Partnership brings together two leaders in next-generation genetic medicines to engineer, co-develop and co-commercialize (50:50 profit share) AAV-delivered CRISPR/Cas-based therapeutics for up to six...
Arbor Biotechnologies Appoints Industry Veteran R. Nolan Townsend to Board of Directors
November 07, 2023 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies Appoints Ajim Tamboli as Chief Financial Officer
August 29, 2023 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies Appoints Deanna M. Petersen as Chief Business Officer
August 07, 2023 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced the...
Arbor Biotechnologies to Present at the Stifel 2023 Tailoring Genes: Genetic Medicines Day
May 23, 2023 07:00 ET
|
Arbor Biotechnologies Inc
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced Devyn Smith,...